New treatment approach effectively treats the most aggressive forms of prostate cancer

The FDA has re­ject­ed Lykos’ MD­MA-as­sist­ed treat­ment for pa­tients with post-trau­mat­ic stress dis­or­der, a ma­jor set­back for the com­pa­ny that had hoped to trans­late more

Contrary to earlier studies, the not-entirely-rare condition known as monoclonal gammopathy of undetermined significance (MGUS) did not appear to raise risk for autoimmune disease when